Management Team

Dr. Bai is the Founder, Chairman of the Board, and Chief Executive Officer of Ambio, Inc.  As Founder and Chairman of the Board, Dr. Bai also provides oversight of Ambiopharm Inc., covering both USA and China operations. Before joining Ambio and AmbioPharm, he was the President and CEO of American Peptide Company where he built the cGMP manufacturing business during his tenure. He was responsible for peptide process development, scale up, and cGMP manufacturing standards. He was involved in numerous peptide process development projects during his tenure, including the process development and manufacture of a 22-amino acid peptide on a 40kg scale by solution phase chemistry.

Mr. Hughes is an accomplished financial executive with over 25 years of experience, with considerable experience in building and guiding small, growing life science companies.  He brings an in-depth understanding of corporate finance and has expertise in strategic planning, fund raising, financial analysis and reporting, mergers and acquisitions, budgeting and risk management.  Prior to Ambio, he held leadership roles at Stridebio, Selentity Therapeutics and Viamet Pharmaceuticals. 
 
Mr. Hughes is a CPA and holds a B.S. from the University of Maryland, where he double majored in Finance and Accounting. He also holds an MBA from the University of North Carolina.

As President of Ambio, Inc., Dr. Singh is responsible for the company’s global operations in North America, Europe, MENA, LATAM, and Asia. He has over 15 years of experience in R&D and Management. He brings an extensive knowledge of advanced analytical characterization techniques and tactical ideas to resolve complex technology transfers as well as regulatory hurdles. He has been a key player in taking multiple complex generic projects from R&D to commercial stage.

He also plays a key role in developing and maintaining strategic partnerships with various large generic pharmaceutical companies and CDO/CMO/CRO’s globally.